NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's ...
Cemdisiran, an investigational small interfering RNA (siRNA) therapy targeting complement component 5 (C5), met both its primary and a key secondary endpoint in the phase III NIMBLE trial of ...
WATERTOWN, Mass. and NEW HAVEN, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve ...
Zilucoplan is a subcutaneous, self-administered, macrocyclic peptide inhibitor of complement component 5. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ...
Credit: Shutterstock. Zilucoplan is a synthetic, macrocyclic peptide inhibitor of complement component 5. Positive topline results were announced from a phase 3 study evaluating the efficacy and ...
PHOENIX – Generalized myasthenia gravis patients had dramatically lower incidence of flares and crises after starting on the complement component 5 inhibitor eculizumab (Soliris), data from a ...
In the version of this article initially published, the numbers in the 'R sym ' row in Table 1 are in the wrong columns. The error has been corrected in the HTML and ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results